Heart Pump Devices Market Size & Growth Forecast 2026–2035, By Segments (Type, Product, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Heart Pump Devices Market size was valued at USD 3.32 Billion in 2025 and is anticipated to grow at a 13.5% CAGR from 2026 to 2035, reaching USD 11.78 Billion by 2035. The industry revenue for 2026 is assessed at USD 3.72 billion.

• Base Year Value (2025): USD 3.32 Billion
• CAGR (2026-2035): 13.5%
• Forecast Year Value (2035): USD 11.78 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Heart Pump Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 55.22% share due to advanced cardiac care infrastructure, specialized hospitals, and strong use of ventricular assist devices supported by high procedural volumes and monitoring systems.
  • Asia Pacific is growing at 15.12% CAGR due to rising cardiovascular disease burden, improved access to advanced hospital care, and expanding adoption of device-based cardiac support in tertiary centers.

• Segment Momentum:

  • Implanted Heart Pump Devices held a 67.03% market share in 2025 due to their established role in long-term mechanical circulatory support, supporting patient mobility and continuity of care beyond acute hospital treatment.
  • Extracorporeal Membrane Oxygenation (ECMO) is the fastest-growing product segment, driven by increasing demand for immediate heart and lung support in critical care, emergency interventions, and complex short-term stabilization cases.

• Market Expansion Drivers:

  • Rising prevalence of cardiovascular diseases increasing demand for ventricular assist devices.
  • Expanding regulatory approvals for advanced heart pump devices accelerating clinical adoption.
  • Growing integration of AI-assisted cardiac diagnostics improving heart failure intervention outcomes.

• Leading Market Participants:

  Key players in the heart pump devices market include Abbott Laboratories (United States), Abiomed, Inc. (United States), Getinge AB (Sweden), LivaNova PLC (United Kingdom), Berlin Heart GmbH (Germany), SynCardia Systems, LLC (United States), Jarvik Heart, Inc. (United States), BiVACOR Inc. (United States), Leviticus Cardio Ltd. (Israel), Teleflex Incorporated (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 3.32 Billion
  • Projected Market Size: USD 11.78 Billion by 2035
  • Growth Forecasts: 13.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Implanted Heart Pump Devices (Type) | Ventricular Assist Devices (VADs) (Product) | Hospitals (End-use)
  • Emerging Opportunity Segment: Extracorporeal Heart Pump Devices (Type) | Extracorporeal Membrane Oxygenation (ECMO) (Product) | Cardiac Centers (End-use)

Market Growth Drivers and Industry Trends

Rising prevalence of cardiovascular diseases increasing demand for ventricular assist devices

The rising burden of heart failure and other advanced cardiovascular conditions is pushing more patients into stages where drug therapy and conventional interventions are no longer sufficient, increasing demand for the heart pump devices market. Ventricular assist devices are increasingly being used as bridge-to-transplant, bridge-to-recovery, and destination therapy options, especially as clinicians manage larger volumes of patients with reduced cardiac function and prolonged disease progression. This shifts hospital purchasing and cardiac program investment toward durable and temporary mechanical circulatory support systems, reinforcing market demand as care teams seek devices that can stabilize critically ill patients and extend treatment pathways when donor hearts remain limited.

Expanding regulatory approvals for advanced heart pump devices accelerating clinical adoption

Broader regulatory clearance for newer-generation systems is reducing a key barrier to physician uptake in the heart pump devices market by giving hospitals access to devices with validated safety, usability, and indication-specific labeling. When advanced heart pump devices receive approval for wider patient groups or updated clinical applications, providers are more willing to incorporate them into treatment protocols, procurement plans, and specialized heart failure programs. This approval momentum also strengthens manufacturer positioning with payers and health systems, supporting market expansion as adoption moves from highly selective use toward more routine integration in tertiary and advanced cardiac care settings.

Growing integration of AI-assisted cardiac diagnostics improving heart failure intervention outcomes

AI-assisted cardiac diagnostics are improving how quickly and accurately clinicians identify worsening heart failure, which is influencing market adoption in the heart pump devices market by enabling earlier and more confident intervention decisions. As imaging, monitoring, and predictive tools become better at flagging patients at risk of decompensation, care teams can time escalation to mechanical circulatory support more effectively rather than waiting for severe deterioration. That practical shift matters because earlier patient selection is closely tied to procedural outcomes and resource utilization, making heart pump therapies more clinically actionable for hospitals building data-driven heart failure management pathways.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of cardiovascular diseases increasing demand for ventricular assist devices	2.40%	High	North America, Europe, Asia Pacific	High	Near Term
Expanding regulatory approvals for advanced heart pump devices accelerating clinical adoption	2.00%	High	North America, Europe	High	Mid Term
Growing integration of AI-assisted cardiac diagnostics improving heart failure intervention outcomes	1.60%	Moderate	North America, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading heart pump devices market position in 2025, accounting for a 55.22% share. This leadership is underpinned by the region’s advanced cardiac care infrastructure, broad availability of specialized hospitals, and established use of mechanical circulatory support in acute and chronic heart failure management. In practice, strong clinical familiarity with ventricular assist technologies, higher procedural volumes, and access to intensive post-implant monitoring support continued adoption across major treatment centers.

Asia Pacific is projected to expand at a 15.12% CAGR over the forecast period in the heart pump devices market. Growth is being fueled by the rising treatment base for cardiovascular disease, improving access to advanced hospital care, and increasing adoption of device-based cardiac support in large population centers. As more healthcare systems in the region strengthen tertiary care capacity and expand interventional cardiology and cardiac surgery services, usage is accelerating in settings where clinicians are moving beyond conventional drug therapy for severe cardiac cases.

Key Country Insights

United States

Advanced Cardiac Support

The U.S. heart pump devices market focuses on expanding access to mechanical circulatory support for advanced heart failure management. Healthcare providers continue integrating next-generation devices that improve procedural efficiency and support long-term patient care strategies.

Japan

Minimally Invasive Adoption

Japan advances heart pump device utilization by encouraging minimally invasive treatment approaches for patients requiring mechanical circulatory support. Hospitals continue evaluating compact device designs that complement evolving cardiovascular care practices and long-term clinical management.

South Korea

Hospital Technology Upgrades

South Korea strengthens the heart pump devices market through investments in advanced cardiac care infrastructure and specialized treatment programs. Healthcare providers increasingly adopt innovative support systems that enhance procedural capabilities for complex cardiovascular cases.

Germany

Specialized Cardiac Care

Germany emphasizes heart pump device adoption within specialized cardiovascular centers performing complex heart failure interventions. Clinical teams prioritize technologies that integrate with established treatment pathways while supporting improved patient management and procedural precision.

France

Integrated Heart Failure Care

France prioritizes heart pump devices within multidisciplinary heart failure treatment programs that combine surgical expertise and long-term patient monitoring. Clinical adoption increasingly reflects efforts to optimize outcomes through coordinated cardiovascular care pathways.

Italy

Cardiac Procedure Enhancement

Italy expands heart pump device utilization by improving capabilities across tertiary care hospitals treating advanced cardiovascular conditions. Italian clinicians continue adopting technologies that strengthen procedural efficiency while supporting comprehensive heart failure management.

Segment Leadership and Growth Trends

  Type Segment Analysis: Implanted Heart Pump Devices (Largest Segment) vs Extracorporeal Heart Pump Devices (Fastest-Growing Segment)

Implanted Heart Pump Devices held the leading position in the heart pump devices market in 2025, accounting for a 67.03% share. Their leadership is underpinned by their established role in long-term mechanical circulatory support, particularly for patients who require ongoing assistance beyond acute hospital intervention. In the heart pump devices market, implanted systems remain the preferred option where continuity of support, patient mobility, and integration into longer-term treatment pathways are central to clinical use, which helps preserve their dominant share.

Extracorporeal Heart Pump Devices are emerging as the fastest-growing segment in the heart pump devices market as demand rises for rapid-deployment support in critical care settings. Their growth is being encouraged by the practical need for short-term circulatory assistance in acute cardiac events and emergency interventions, where immediate stabilization is the priority. Compared with implanted alternatives, extracorporeal systems gain momentum because they can be used in time-sensitive hospital environments without the same long-term procedural pathway, making them increasingly relevant in intensive and perioperative care.

Product Segment Analysis: Ventricular Assist Devices (VADs) (Largest Segment) vs Extracorporeal Membrane Oxygenation (ECMO) (Fastest-Growing Segment)

By 2025, Ventricular Assist Devices (VADs) represented the largest product category in the heart pump devices market with a 66.45% share. This leadership reflects their established use in managing advanced heart failure where sustained ventricular support is required over extended periods. Within the heart pump devices market, VADs continue to hold the largest share because they fit well into defined treatment pathways for bridge-to-transplant and longer-duration support, reinforcing their position across specialized cardiac care settings.

Extracorporeal Membrane Oxygenation (ECMO) is the fastest-growing product segment in the heart pump devices market, aided by its expanding use in acute cardiopulmonary support. Growth is centered on situations where patients need immediate combined heart and lung assistance, especially in critical care and emergency hospital settings. ECMO is gaining momentum faster than other product options because it addresses urgent short-term stabilization needs in highly complex cases, making it increasingly valuable where rapid intervention and intensive monitoring are essential.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Implanted Heart Pump Devices, Extracorporeal Heart Pump Devices	Implanted Heart Pump Devices	Extracorporeal Heart Pump Devices
Product	Ventricular Assist Devices (VADs), Total Artificial Hearts (TAH), Intra-Aortic Balloon Pumps (IABPs), Extracorporeal Membrane Oxygenation (ECMO)	Ventricular Assist Devices (VADs)	Extracorporeal Membrane Oxygenation (ECMO)
End-use	Hospitals, Cardiac Centers, Research Institutes	Hospitals	Cardiac Centers

Competitive Landscape and Market Positioning

Top players in the heart pump devices market:

1. Abbott Laboratories (United States)

2. Abiomed Inc. (United States)

3. Getinge AB (Sweden)

4. LivaNova PLC (United Kingdom)

5. Berlin Heart GmbH (Germany)

6. SynCardia Systems LLC (United States)

7. Jarvik Heart Inc. (United States)

8. BiVACOR Inc. (United States)

9. Leviticus Cardio Ltd. (Israel)

10. Teleflex Incorporated (United States)

The heart pump devices market is witnessing strong technological progress driven by rising demand for advanced cardiac support systems and minimally invasive treatment solutions. Manufacturers are focusing on compact device designs, enhanced durability, and improved patient monitoring capabilities to support long-term cardiac care. Increasing clinical research activities and healthcare investments are also contributing to product advancement within the market.

Industry Development/News

Company Name	Date	Key Development
J&J	May-26	The company issued a safety correction regarding its Impella heart pump controller after identifying a technical defect that causes the controller to temporarily stop for 35 seconds. The resulting brief disruption in circulatory support was linked to clinical complications, including two injuries and one death.
CARMAT	Dec-23	The medical technology company opened its second production facility in Bois-d’Arcy, France, following regulatory approval from notified body DEKRA. This strategic capacity expansion allows the manufacturer to scale production capacity of its Aeson total artificial heart to 500 units annually.
American College of Cardiology	Mar-25	The ACC and American Heart Association updated treatment guidelines, upgrading the clinical recommendation of Impella heart pumps in STEMI-related cardiogenic shock from Class 2b to 2a. The revision recognizes improved patient survival benefits, validating the system's role in critical circulatory care.
BiVACOR Inc.	Feb-24	The enterprise secured a USD 13 million grant from the Australian Government’s Medical Research Future Fund via the Artificial Heart Frontiers Program. The non-dilutive capital supports clinical trials, the implementation of a wireless power ecosystem, and long-term controller design optimization for its total artificial heart.
Abbott	Apr-23	The healthcare corporation obtained two expanded clearances from the U.S. FDA for its CentriMag Blood Pump system. The regulatory approvals authorize longer-term clinical use of the pump in adult patients requiring temporary mechanical circulatory support during extended extracorporeal membrane oxygenation (ECMO) procedures.